GENE ONLINE|News &
Opinion
Blog

Trials & Approvals
GIVLAARI to Enter European Market Following EMA Approval
2020-03-04
NERLYNX-XELODA Combo Bags FDA Approval for HER2 Positive Breast Cancer Treatment
2020-02-27
EXBLIFEP Surpasses Phase III, Presents Novel Solution for Antibiotic Resistance Crisis in Treating Complicated UTI
2020-02-26
FDA Approval of Cholesterol Lowering Drug, NEXLETOL, A Value-Add to Existing Treatments
2020-02-25
Relief for Patients as Baudax Bio’s Non-Opioid Analgesic Wins FDA Approval
2020-02-23
VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial
2020-02-22
VEGF Inhibitor, Beovu Gets EC Approval for Wet Age-Related Macular Degeneration Treatment
2020-02-18
GSK Wins EMA Approval to Market Multiple Myeloma Treatment
2020-02-16
Yet Another Feather in Merck’s Crown, Keytruda Meets Endpoint in Phase 3 Trial for Triple Negative Breast Cancer
2020-02-13
First AI-Guided Ultrasound ECHO Software Approved for Marketing
2020-02-12
Trevena Inc. Gives Oliceridine Approval Another Shot
2020-02-11
Sanofi’s BTK Inhibitor Meets Primary Endpoint in Phase 2 Trial Amidst Criticism
2020-02-07
First AI-Designed Drug to Enter Phase I Clinical Trial
2020-02-05
Seqirus’ AUDENZTM, a Vaccine against Potential Flu Epidemic Gets FDA Approval
2020-02-05
R&D
Insmed Soaring High with Positive Phase II Results for Non Cystic Fibrosis Bronchiectasis Drug, INS1007
2020-02-03
1 44 45 46 47 48 50
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top